摘要
目的 探索术前抗病毒治疗和不同类型的抗病毒治疗药物对乙肝相关肝癌患者微血管侵犯(MVI)的影响。方法 分析581例接受手术治疗的肝癌患者的临床病理资料。采用Logistic回归分析评估MVI的相关因素。结果 纳入的患者中,254(43.7%)例患者MVI阳性。根据MVI是否阳性将患者分为MVI阳性组和阴性组。HBV-DNA水平、谷草转氨酶、甲胎蛋白、血小板、肿瘤直径、肿瘤多发、卫星灶、差分化和抗病毒情况在两组之间存在统计学差异。男性、甲胎蛋白>400μg/L、肿瘤直径>5.5 cm、肿瘤多发、卫星灶和差分化是MVI发生的独立危险因素,恩替卡韦抗病毒治疗≥3个月(OR:0.557,95%CI:0.320~0.969)是MVI发生的独立保护因素。结论 术前恩替卡韦抗病毒治疗≥3个月可降低乙肝相关肝癌患者MVI的发生率。
Objective To explore the effect of preoperative antiviral therapy and different types of antiviral drugs on microvascular invasion(MVI)in patients with hepatitis B associated liver cancer.Methods The clinicopathological data of 581 patients with hepatocellular carcinoma treated by surgery were analyzed.Logistic regression analysis was used to evaluate the related factors of MVI.Results Among the included patients,254(43.7%)patients were MVI positive.The patients were divided into MVI positive group and negative group according to whether MVI was positive or not.There were significant differences in HBV-DNA levels,aspartate aminotransferase,alpha-fetoprotein,platelets,tumor diameter,tumor frequency,satellite foci,poor differentiation and antiviral status between the two groups.Male,alpha-fetoprotein>400μg/L,tumor diameter>5.5 cm,multiple tumors,satellite foci and poor differentiation were independent risk factors for MVI.Entecavir antiviral therapy≥3 months(OR:0.557,95%CI:0.320-0.969)was independent protective factor for MVI.Conclusion Preoperative entecavir antiviral therapy for≥3 months can reduce the incidence of MVI in patients with HBV-related liver cancer.
作者
闻朝建
方向春
嵇惠宇
刘现忠
缪坤
郝保兵
WEN Chaojian;FANG Xiangchun;JI Huiyu;LIU Xianzhong;MIAO Kun;HAO Baobing(Department of Oncology,Tianchang People s Hospital,Tianchang 239300,China)
出处
《临床肿瘤学杂志》
CAS
2022年第10期917-921,共5页
Chinese Clinical Oncology
